Madhu Kumar

Tim Lugo

- On **September 19, 2025**, Akari Therapeutics Plc amended its **April 2023 Notes** and **Warrants**, extending the notes' maturity to **August 31, 2026**, and the warrants' expiration to **August 31, 2030**.  **[1541157_0001493152-25-014962_form8-k.htm:1]**  The conversion and exercise prices for both were adjusted to **$0.81 per ADS**.  **[1541157_0001493152-25-014962_form8-k.htm:1]** 
- The company completed the **second tranche** of its **August 2025 Notes Offering** on **September 24, 2025**, issuing **$625,000** in aggregate principal amount of notes for a purchase price of **$500,000**, bringing the total principal issued to **$3.5 million**.  **[1541157_0001493152-25-014962_form8-k.htm:3]** 
- Akari Therapeutics Plc also announced on **September 24, 2025**, positive preclinical data for its novel antibody drug conjugate (ADC) payload, **PH1**, showing its potential to treat prostate cancer by suppressing AR-V7 expression.  **[1541157_0001493152-25-014962_form8-k.htm:2]**

Akari Therapeutics Amends Debt and Warrants, Closes Debt Tranche, and Reports Preclinical Data

- Akari Therapeutics Plc entered into an **Ordinary Share Purchase Agreement** with White Lion Capital, LLC on **August 29, 2025**, allowing the company to sell up to **$25,000,000** in newly issued Ordinary Shares.  **[1541157_0001641172-25-026032_form8-k.htm:1]** **[1541157_0001641172-25-026032_ex10-1.htm:0]** 
- The agreement provides Akari Therapeutics Plc with the **right, but not the obligation**, to sell shares over a **Commitment Period** ending on the earlier of the full amount being purchased or **August 29, 2028**.  **[1541157_0001641172-25-026032_form8-k.htm:1]** 
- Sales under the agreement are contingent upon a **registration statement** covering the resale of the shares being declared effective by the SEC.  **[1541157_0001641172-25-026032_form8-k.htm:1]** 
- As consideration for the agreement, Akari Therapeutics Plc will pay a **document preparation fee of $15,000** and additional cash commitment fees based on aggregate purchase notices.  **[1541157_0001641172-25-026032_form8-k.htm:2]**

Akari Therapeutics (AKTX)